Establishing low‐density lipoprotein apheresis tolerability in patients with prior anaphylactoid reactions to lipoprotein apheresis using magnesium sulfate
- 18 February 2021
- journal article
- research article
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 36 (3), 437-442
- https://doi.org/10.1002/jca.21884
Abstract
Background Lipoprotein apheresis (LA) tolerability is a key factor for the utilization of this therapy. Common reactions to LA are hypotension and nausea. Serious reactions include severe hypotension and anaphylactoid reactions (0.13%‐1.3% and 0.2%‐0.4%, respectively). The bradykinin response drives these reactions and can worsen with the use of angiotensin‐converting‐enzyme inhibitors. Efforts to mitigate these reactions are necessary for the tolerability of LA with a dextran sulfate‐adsorption (DSA) system. Materials and Methods In an effort to increase apheresis tolerability, seven patients at The University of Kansas, Department of Clinical Pharmacology, who had prior anaphylactoid reactions (defined as general cutaneous flushing, nausea/vomiting, tongue swelling, lightheadedness, and hypotension) to the DSA despite pharmacologic intervention, were treated with pre‐LA intravenous magnesium adapted from a protocol developed by co‐author Eliaz. This protocol consists of 1.5 g of magnesium sulfate administered over 45 minutes. All seven patients were treated with intravenous magnesium sulfate immediately before LA. Results No episodes of anaphylactoid reactions during LA have been reported to date. Conclusions Magnesium infusion before DSA can be utilized to establish tolerability in patients with prior anaphylactoid reactions to LA. Proposed mechanisms include temporary stabilization of the negative‐positive interactions of the dextran sulfate filter leading to a reduction of circulating bradykinin, reduction of nitric oxide, and reduction of the sympathetic response to LA.Keywords
This publication has 24 references indexed in Scilit:
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special IssueJournal of Clinical Apheresis, 2019
- Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a)Pathology, 2019
- Prospective crossover study for a standardized comparison of the dextrane sulfate whole blood and plasma apheresis system in patients with cardiovascular disease and severe dyslipidemiaAtherosclerosis Supplements, 2017
- Toward an international consensus—Integrating lipoprotein apheresis and new lipid-lowering drugsJournal of Clinical Lipidology, 2017
- Factor XII Contact ActivationSeminars in Thrombosis and Hemostasis, 2017
- Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial HypercholesterolemiaJournal of the American Heart Association, 2016
- Lipoprotein apheresis reduces circulating galectin-3 in humansJournal of Clinical Apheresis, 2015
- Familial Hypercholesterolemia—Epidemiology, Diagnosis, and ScreeningCurrent Atherosclerosis Reports, 2015
- Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking AntibodyOnline Journal of Public Health Informatics, 2014
- Contact Activation in Low‐density Lipoprotein Apheresis SystemsArtificial Organs, 2005